Why Spark Therapeutics stock price dropped by 40% this morning
Spark Therapeutics ’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment.
Preliminary clinical data showed the gene therapy treatments produced significant reductions in bleeding rates, but yielded mu ch lower increases in levels of factor VIII — the clotting protein missing in hemophilia A patients.
California-based BioMarin Pharmaceutical released study results on Saturday of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Bleeding | Gene Therapy | Genetics | Haemophilia | Health Management | Hemophilia | Pharmaceuticals | Study